Evidence map›Paper›PMID 42032663›Full record

ReviewBMC medicine2026

Introducing the need for a consensus-based framework for protocol modifications to improve trial trustworthiness.

Cora Burgwinkel, Manon Gicquel, Isabelle Boutron, Sylvie Chevret, Leonhard Held, David Moher, Florian Naudet, Clara Locher

Abstract readReview
In one paragraph

Review in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Cora BurgwinkelEpidemiology, Biostatistics and Prevention Institute (EBPI) and Center for Reproducible Science and Research Synthesis (CRS), Universität Zürich, Zurich, Switzerland.
Manon GicquelUniv Rennes, CHU Rennes, Inserm, Centre d'investigation clinique de Rennes (CIC1414), service de pharmacologie clinique, Institut de recherche en santé, environnement et travail (Irset)-UMR_S 1085, 35000, Rennes, France.
Isabelle BoutronUniversité Paris Cité and Université Sorbonne Paris Nord, Inserm, INRAe, Centre for Research in Epidemiology and Statistics (CRESS), F-75004, Paris, France.
Sylvie ChevretECSTRRA TEam, IRSL, U1342, Université Paris Cité, Inserm, 75010, Paris, France.
Leonhard HeldEpidemiology, Biostatistics and Prevention Institute (EBPI) and Center for Reproducible Science and Research Synthesis (CRS), Universität Zürich, Zurich, Switzerland.
David MoherSenior Scientist, Ottawa Hospital Research Institute. Full professor, School of Epidemiology and Public Health, University of Ottawa; Full professor, Institute of Health Policy, Management & Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.
Florian NaudetUniv Rennes, CHU Rennes, Inserm, Centre d'investigation clinique de Rennes (CIC1414), service de pharmacologie clinique, Institut de recherche en santé, environnement et travail (Irset)-UMR_S 1085, 35000, Rennes, France.
Clara LocherUniv Rennes, CHU Rennes, Inserm, Centre d'investigation clinique de Rennes (CIC1414), service de pharmacologie clinique, Institut de recherche en santé, environnement et travail (Irset)-UMR_S 1085, 35000, Rennes, France. clara.locher@chu-rennes.fr.

Funding

Horizon-MSCA.2022-DN 110120360Swiss State Secretariat for Education, Research and Innovation (SERI) 23.00303
6 · The paper itself

Abstract

backgroundTransparency in randomized controlled trials (RCTs) has substantially improved in recent years, notably through trial registration and public availability of protocols and statistical analysis plans (SAPs). However, the reporting of protocol and SAPs modifications remains insufficiently standardized. As a result, even when these documents are publicly available, it is often challenging and time-consuming to identify what changes were made, why they were implemented, and whether they may affect the trustworthiness of the trial results. ARGUMENTS: In this paper, we advocate for the development of a consensus-based framework for protocol modifications in RCTs. This need arises from the inherent tension between the necessity and the risks of protocol modifications. On the one hand, such modifications are often essential to address unforeseen operational, scientific, or ethical challenges. On the other hand, they may introduce bias and undermine confidence in trial findings, particularly when changes are data-driven or insufficiently justified. Although major transparency initiatives have strengthened trial reporting, important gaps persist. We review empirical evidence demonstrating the prevalence and nature of such modifications and discuss their potential implications for the validity, interpretation, and credibility of trial findings. Furthermore, readers, reviewers, and decision-makers face substantial challenges in identifying, understanding, and evaluating the potential impact of protocol changes. In the absence of standardized reporting, key information remains dispersed across multiple documents, placing an unreasonable burden on stakeholders to identify, interpret, and assess protocol modifications and their implications for the credibility of trial results.

conclusionsStandardized and transparent reporting of protocol modifications is essential to ensure that their nature, timing, and rationale can be clearly understood and critically evaluated. We therefore advocate for the development of a consensus-based reporting framework, informed by a Delphi process, to improve transparency, facilitate critical appraisal, and strengthen confidence in RCT findings.

Indexed as

Clinical Trial Protocols as TopicConsensusResearch DesignHumansRandomized Controlled Trials as TopicProtocol modificationsReporting standardsResearch reproducibilitySelective reporting

Identifiers

PMID42032663
PMCPMC13245086

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.